Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Journal Of Clinical Oncology 2022, 40: 4506-4506. DOI: 10.1200/jco.2022.40.16_suppl.4506.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBladder cancer patientsPathologic responseTreatment responseCell-free DNA methylationCancer patientsMuscle-invasive bladder cancer patientsMuscle-invasive bladder cancerCycles of chemotherapyStandard neoadjuvant chemotherapyCooperative group trialsStandard of careProspective cooperative group trialsIndependent predictive abilityRadical cystectomyPredictive biomarkersPathologic respondersBladder cancerGroup trialsMR scoreBlood samplesChemotherapyPatientsPlasma samplesResponse scores